GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » BRIM Biotechnology Inc (ROCO:6885) » Definitions » Notes Receivable

BRIM Biotechnology (ROCO:6885) Notes Receivable : NT$0.00 Mil (As of Jun. 2024)


View and export this data going back to 2022. Start your Free Trial

What is BRIM Biotechnology Notes Receivable?

BRIM Biotechnology's Notes Receivable for the quarter that ended in Jun. 2024 was NT$0.00 Mil.


BRIM Biotechnology Notes Receivable Historical Data

The historical data trend for BRIM Biotechnology's Notes Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BRIM Biotechnology Notes Receivable Chart

BRIM Biotechnology Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
Notes Receivable
- - - - -

BRIM Biotechnology Semi-Annual Data
Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24
Notes Receivable Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

BRIM Biotechnology Notes Receivable Calculation

Notes Receivable is an unconditional promise to receive a definite sum of money at a future date(s) within one year of the balance sheet date or the normal operating cycle, whichever is longer.


BRIM Biotechnology Notes Receivable Related Terms

Thank you for viewing the detailed overview of BRIM Biotechnology's Notes Receivable provided by GuruFocus.com. Please click on the following links to see related term pages.


BRIM Biotechnology Business Description

Traded in Other Exchanges
N/A
Address
No.1, Alley 30, Lane 358, Ruiguang Road, 8th Floor, Neihu District, Taipei, TWN, 11492
BRIM Biotechnology Inc applies integrated and efficient translational science to develop new treatments that help combat and cure disease. Its lead product candidate, BRM421, is on track to treat Dry Eye Syndrome (DES) which treats and repairs corneal damage. Its product help to treat Neurotrophic Keratitis, osteoarthritis, and corneal damage repair.

BRIM Biotechnology Headlines

No Headlines